Supplementary Figure. A. Difference in frequency of CD8+ staining by IHC in control or PIK3CA H1047R tumors treated with PD-1 blockade, quantification of Figure 2A. B. tSNE projection of scRNA-seq profiles from CD45+ tumor infiltrating immune cells from control or PIK3CA H1047R MC38 tumors, colored by tumor of origin in tSNE. C. Gene expression matrix from single-cell RNA-seq experiment characterizing expression of lineage-defining genes in cell clusters. D. Frequency of indicated immune cell types by flow cytometry from control or PIK3CA H1047R MC38 tumors on day 14. E. Correlation of MYC and HRAS and mRNA levels with CCR2 mRNA levels in indicated cancers. Volcano plot showing the Spearman’s correlation and estimated significance from RNA-seq data across TCGA cancer types calculated by TIMER (Tumor Immune Estimation Resource) and adjusted for tumor purity[27]. Each dot represents a cancer type in TCGA; red dots indicate significant correlations (P < 0.05). F. Ccl2 transcript abundance measured by qPCR in control and PIK3CA H1047R MC38 cells after transfection with sgRNA targeting Ccl2. Data are mean±s.d. G. Ccl2 protein abundance in cell supernatant measured by ELISA in control and PIK3CA H1047R MC38 cells after transfection with sgRNA targeting Ccl2 or control guide. Data are mean±s.d. H. Frequency of Ccr2hi myeloid cells in control and PIK3CA H1047R MC38 tumors after transfection with sgRNA targeting Ccl2 or control guide.